Atrasentan FDA Approval Status
Last updated by Melisa Puckey, BPharm on Jan 30, 2024.
FDA Approved: No
Generic name: atrasentan
Company: Novartis Pharmaceuticals Corporation
Treatment for: Nephropathy
Atrasentan is an investigational oral endothelin A receptor antagonist (ERA) that is used for proteinuria reduction in patients with IgA nephropathy (IgAN).
- Atrasentan is being investigated to help reduce proteinuria in patients with IgA nephropathy (IgAN).
- Atrasentan works by blocking the endothelin A receptor.
IgA nephropathy (IgAN)
IgAN is a progressive, rare kidney disease that mainly affects young adults.
Immunoglobulin A (IgA) is an antibody blood protein that's part of your immune system. IgAN is caused by an autoimmune reaction to an abnormal form of IgA, resulting in the formation of immune complexes that deposit in the kidney. These immune complexes trigger inflammation that can lead to progressive kidney damage and loss of kidney function. Some people who have IgAN with persistent higher levels of protein in their urine (proteinuria) may progress to kidney failure within 10 years.
Effective therapies for IgAN may be able to help slow the progression to kidney failure.
Development timeline for atrasentan
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
